| Factor Information | |
|---|---|
| Data ID | 826 |
| Factor | Galectin‐3 (μmol/L) |
| Description | Some biomarkers play important roles in the endothelial dysfunction of patients with pulmonary arterial hypertension (PAH), including nitric oxide (NO), endothelin-1 (ET-1), asymmetric dimethylarginine (ADMA), galectin-3 (Gal-5), B-type natriuretic peptide (BNP), and uric acid. |
| Biomarker | YES |
| Classification | E2 (physiological factor - biochemical index) |
| Association | |
|---|---|
| Application | treatment and prognosis |
| Objective | This study aimed at selecting effective biomarkers that could be used to assess the severity of CHD–PAH in patients and investigating the effect of iloprost at the level of biomarkers. |
| p Value | <0.05 |
| Conclusion | Iloprost could affect the expression of Galectin-3 and, therefore, the process of fibrosis could be influenced by iloprost. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 484 |
| CHD Type | isolated CHD |
| CHD Subtype | ASD/VSD/PDA |
| Reference | |
|---|---|
| PMID | 28608969 |
| Year | 2017 |
| Title | Effect of iloprost on biomarkers in patients with congenital heart disease-pulmonary arterial hypertension. |
| Sample | ||
|---|---|---|
| Population | patients with CHD-PAH | |
| Source | blood | |
| Region | Shanghi, China | |
| Method | This prospective and observational study enrolled patients with CHD‐PAH. | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | iloprost negative group[ING] -2 after inhaling iloprost and occlusion(Treatment) | iloprost negative group[ING] -1 before inhaling iloprost after occlusion (Control) |
| Number | 7(IPG-2) | 7(IPG -1) |
| Age | ING:49.52±14.43 years | ING:49.52±14.43 years |
| Gender (Male: Female) | 5:14 | 5:14 |
| Marker Level | 5.00±2.76 (ING‐2, mean level of biomarkers after inhaling iloprost after occlusion) | 6.12±3.90 (ING‐1, mean level of biomarkers before inhaling iloprost after occlusion) |
